2020 American Transplant Congress
Preemptive Direct Acting Antiviral Therapy as Prophylaxis in Donor HCV-Positive to Recipient HCV-Negative Solid Organ Transplant: a Comprehensive Review
Gastroenterology, Louisiana State University of Health Sciences Shreveport, Shreveport, LA
*Purpose: With the advent of highly effective and safe oral Direct acting Antiviral agents (DAAs), several transplant centers have adopted protocols for using HCV positive…2020 American Transplant Congress
Cytomegalovirus Infection and Outcomes in Pancreas Transplant Recipients in the Prophylaxis Era
1UW Health, Madison, WI, 2UWMF, Madison, WI
*Purpose: Evaluate epidemiology and outcomes of cytomegalovirus infection (CMV) in pancreas transplant recipients (PTR) in the current era of valganciclovir (VGC) prophylaxis (PPX)*Methods: Adult PTRs…2020 American Transplant Congress
Comparison of Prophylaxis Strategies for CMV Infection in Liver Transplant Recipients
The Ohio State Wexner Medical Center, Columbus, OH
*Purpose: The best strategy to prevent cytomegalovirus (CMV) following liver transplantation is not defined for intermediate risk recipients (recipient seropositive (R+) regardless of donor status).…2020 American Transplant Congress
Brincidofovir for Adenovirus Disease in Adult Renal Transplant Recipients: A Case Series
*Purpose: Adenovirus infection can lead to disease in solid organ transplant recipients, including disease of the allograft. Treatment options for severe disease are limited. Brincidofovir…2020 American Transplant Congress
Utilization of Organs from Donors Exposed to Hepatitis C: ? Standard of Care
*Purpose: To report the results of a clinical program to utilize livers and kidneys from donors exposed to Hepatitis C.*Methods: We initially started to explore…2020 American Transplant Congress
Viral Kinetics of De Novo HCV Infection and Response to Antiviral Therapy in Liver and Kidney Transplant Recipients Receiving HCV-Viremic Donors
*Purpose: There is general agreement that expanded use of organs from HCV-viremic donors is desirable, including in recipients without HCV infection. However, the optimal treatment…2019 American Transplant Congress
Oral Ribavirin Therapy for Respiratory Syncytial Virus (RSV) in Lung Transplant Recipients: The Impact of Policy Implementation on Cost and Appropriate Use
Henry Ford Hospital, Detroit, MI
*Purpose: RSV is a leading cause of viral infections in lung transplant recipients and is associated with significant morbidity and mortality. While the role of…2019 American Transplant Congress
REHANNA: Renal Transplants in Hepatitis C Negative Recipients with Nucleic Acid Positive Donors with Short Course Direct Acting Antiviral Prophylaxis
Johns Hopkins University School of Medicine, Baltimore, MD
*Purpose: To mitigate the current organ shortage and underutilization of hepatitis C-infected deceased donor (HCV D+) organs, we evaluated the use of HCV D+ kidneys…2019 American Transplant Congress
Long-Term Efficacy of Direct-Acting Antiviral Agents
Beijing Friendship Hospital, Capital Medical University, Beijing, China
*Purpose: Long-term efficacy of direct-acting antiviral agents (DAAs) therapy in kidney transplant recipients was unknown. Thus, we aimed to evaluate it in a Chinese cohort…2019 American Transplant Congress
Excellent Success with Safety and Efficacy of Direct-Acting Anti-Viral HCV Drugs in Kidney Transplant Recipients Using an Evolving Regimen. A Single Institution Experience
Indiana University School of Medicine, Indianapolis, IN
*Purpose: Chronic Hepatitis C Virus (HCV) infection has a negative impact on graft survival. Prior treatments were poorly tolerated and had minimal cure rates. We…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 14
- Next Page »